Abivax shares drop 31% over three months and remain below their averages
The Parisian biotech specialising in inflammatory diseases recovers at midday, in a SBF 120 that is edging higher. The rebound follows several weeks of selling pressure and leaves the stock well below its medium-term benchmarks, while bearish bets remain in place.
A rebound that leaves the stock below its three moving averages
Abivax gains 1.75% to €78.50, while the SBF 120 rises 0.37%. The rebound remains modest compared with the 31.2% decline over three months.
The share price is below the 20-day moving average (a gap of 1.26%), the 50-day moving average (8.17%) and the 200-day moving average (20.11%), so today's move does not change the underlying configuration.
The support at €76.05, broken last Friday, is less than 3% below the current price. The RSI at 45 remains neutral, consistent with a stock that is stabilising after its fall without having initiated a recovery.
Short positions at 5.69% of capital, slightly up over one month
According to the disclosures consulted, five funds together hold 5.69% of the capital sold short, compared with 5.35% thirty days ago.
The increase is 0.34 points: it indicates that institutional investors remain positioned against the stock or are hedging an exposure, without signalling a sharp reversal. This cumulative level, above 3%, deserves to be monitored alongside the trend in the share price.
Abivax is listed both on Euronext Paris and, in the form of ADSs, on the Nasdaq, two lines that trade at almost the same price. The Paris share remains eligible for the PEA, which is not the case for the US ADS.
